alle iol eat:

Aditya Vision Limited

CIN : L32109BR1999PLC008783
An ISO 9001:2015 Certified Company
a BSE Listed Company

March 31, 2022

BSE Limited

Phiroze Jeejeebhoy Towers

Dalal Street
Mumbai-400 001

SCRIP Code: 540205

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure

Requirements) Regulations, 2015

Dear Sir(s)

In Compliance of Regulation 30 of SEBI (Listing Obligations and Disclosure

Requirements) Regulations, 2015 we wish to inform that today, Company has
opened its 79° Showroom at Shree Krishna Bhawan, Dimna Road, Mango,
Jamshedpur- 831012, Jharkhand.

This is for your information and record.

Thanking you

Yours faithfully

For Aditya Vision Limited

For Aditya Vision Limited

Sels—
puonra
Akanksha Arya
Company Secretary

PUL
Registered Office : 1st, 2nd & 3rd Floor, Aditya House, M-20, Road No. 26, 5.K.Nagar, Patna-800 001 INDIA
T: +91 612 25206 74/854, E :headoffice@adityavision.in
Helpline : 1800 1218 111, website :www.adityavision.in
GSTIN : 10AAECA0801E125
GTPL Hathway Limited
GIN : L64204GJ2006PLC048908
Registered Office : 202, 2nd Floor, Sahajanand Shopping Centre,
Opp. Swaminarayan Temple, Shahibaug, Ahmedabad-380004, Gujarat.
Phone: 079-25626470 Fax: 079-61400007

Ref. No.: GTPL/SE/2022

March 31, 2022

BSE Limited N ational Stock Exchange of India Limited

Phiroze Jeejeebhoy Towers, Exchange Plaza,
Dalal Sti-eet, Plot No. C/1, G Block,
Mumbai 400 001 Bandra Kurla Complex, Bandra (East),
Mumbai - 400051

Scrip Code: 540602 Trading Symbol: GTPL

Dear Sir/ Madam,

Su bject: Sale of stake in 9 (nine) w holly owned subsidiary companies

Ref: Disclosu re pursuant to Regulation 30 of the Securities and Exch an ge Board of India
(Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is to inform that the Company has entered into Share Transfer Agreement(s) on March 30,
2022 for disposing its entire 100.00% stake i.e. 10,000 Equity Shares each of the following 9
(nine) wholly owned subsidiary companies for which the Company has received total
consideration of Rs. 9,00,000 (Rupees Nine Lakhs only):

1. GTPL Anjali Cable Private Limited ("GTPL Anjali");

2. GTPL Blue Bell Network Private Limited ("GTPL Blue Bell")
3. GTPL Deesha Cable Net Private Limited ("GTPL Deesha")
4. GTPL Meghana Distributors Private Limited ("GTPL Meghana")
5. GTPL Surat Telelink Private Limited ("GTPL Surat")
6. GTPL TV Tiger Private Limited ("GTPL TV Tiger")
7. GTPL Vidarbha Telelink Private Limited ("GTPL Vidarbha")
8. GTPL Video Vision Private Limited ("GTPL Video Vision")
9. SCOD18 Networking Private Limited ("SCOD18")

Pursuant to the same, GTPL Anjali, GTPL Blue Bell, GTPL Deesha, GTPL Meghana, GTPL
Surat, GTPL TV Tiger, GTPL Vidarbha, GTPL Video Vision and SCOD18 have ceased as
subsidiaries of the Company.

The said wholly owned subsidiaries, being non-operating companies, their contribu tion to the
consolidated turnover of the Company as well as to its Net worth for the FY 2020-21 was NIL.

The Company has sold its entire shareholding of the said wholly owned subsidiaries to
Mr. Deepal< Kumar Yadav and Mr. Divyarajsinh Jadeja. Mr. Deepak Kumar Yadav and
Mr. Divyarajsinh Jadeja do not belong to Promoter/ Promoter Group/ Promoter Companies.

Corporate/Correspondence Office : "GTPL HOUSE" Shree One Building, Opp. Armieda, Nr. Pakwan Cross Road,
Sindhu Bhavan Road, Ahmedabad - 380 059. Phone : 079-61400000 Email : info@gtpl.net Web : www.gtpl.net
GTPL Hathway Limited
CIN : L64204GJ2006PLC048908
Registered Office : 202, 2nd Floor, Sahajanand Shopping Centre,
Opp. Swaminarayan Temple, Shahibaug, Ahmedabad-380004, Gujarat.
Phone: 079-25626470 Fax: 079-61400007

This sale does not fall within Related Party Transaction. Further, the transaction is in the nature
of sale of entire stake in subsidiaries and hence it is not a slump sale.

Thanking you

Yours faithful ,
For GTPL Ha :tway Limited

Hardik Sanghvi
Company Secretary & Compliance Officer
FCS: 7247

Corporate/Correspondence Office : "GTPL HOUSE" Shree One Building, Opp. Armieda, Nr. Pakwan Cross Road,
Sindhu Bhavan Road, Ahmedabad - 380 059. Phone : 079-61400000 Email : info@gtpl.net Web : www.gtpl.net
 Hindustan Oil Exploration Company Limited
‘Lakshmi Chambers’, 192, St. Mary’s Road, Alwarpet, Chennai - 600 018. INDIA.
: 91 (044) 66229000 ● Fax: 91 (044) 66229011 / 66229012
E-mail: contact@hoec.com ● Website: www.hoec.com CIN: L11100GJ1996PLC029880

March 31, 2022 By Online

To
The Listing Department The Corporate Relationship Department
The National Stock Exchange of India Ltd. BSE Limited,
"Exchange Plaza", Bandra Kurla Complex, 1st Floor, P. Jeejeebhoy Towers,
Bandra (East), Mumbai - 400 051 Dalai Street, Mumbai - 400 001
Stock Code: HINDOILEXP Stock Code: 500186

Dear Sirs,

Sub: Submission of information pursuant to Regulation 30 of SEBI (Listing Obligations and

Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations,

2015, we would like to submit the following update on B-80 Project.

The pre-commissioning and safety checks at KGB-Offshore Installation (MOPU) and FSO Prem
Pride (FSO) are complete and the system is ready to receive the first hydrocarbons.

The well opening sequence was followed to bring the first well safely on production, however we
have encountered operational issues and troubleshooting is currently ongoing.

The delay witnessed in the commencement of production from the field being unanticipated,
necessary corrective actions are being taken by the Company, and the field will safely be brought
on line for production as soon as the issues are rectified.

This is for your information and record please.

Yours Sincerely,
For Hindustan Oil Exploration Company Limited

G Josephin Daisy
Company Secretary

Registered Office: ‘HOEC HOUSE’, Tandalja Road, Off Old Padra Road, Vadodara - 390 020. INDIA.
: 91 (0265) 2330766 ● E-mail: contact@hoec.com ● Website: www.hoec.com
31st March 2022

National Stock Exchange of India Ltd, BSE Limited

Exchange Plaza, Bandra Kurla Complex, P.J. Towers, Dalal Street
Bandra (East), Mumbai – 400051. Mumbai - 400001.
Fax No.26598237/26598238 Fax No.22722037/22723121

Name of Scrip: CIGNITITEC Scrip code: 534758

Dear Sir/ Madam,

Sub: Intimation of Schedule of Analyst/ Institutional Investor Meet
We wish to inform you, pursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure
Requirements) Regulations, we give the below schedule of Analyst/Institutional Investor meet for your
information.

Type of
Date Interaction with Company Representative
Interaction
Mr. Krishnan Venkatachary
(Group, Chief Financial Officer),

Mr. Subhendu Pattnaik

01-04-2022 Virtual Meeting East Bridge Capital LLP (VP & Global Head of Marketing & IST)
And
Mr. Sairam Vedam
(Chief Marketing Officer)

The discussion will be mainly on the company and will not involve any unpublished price sensitive information.

Thanking you.

Yours Faithfully,
For Cigniti Technologies Limited

Naga Vasudha
Company Secretary

CC: To all the Designated Employees / Directors /Officers

31st March, 2022

BSE Limited National Stock Exchange of India Ltd.

Corporate Relationship Department Exchange Plaza,
P.J. Towers, Bandra-Kurla Complex,
Dalal Street, Fort, Bandra (East)
Mumbai - 400 001 Mumbai - 400 051
Scrip Code : 506109 Symbol : GENESYS

Sub.: Intimation regarding retirement of Chief Financial Officer

Dear Sirs/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure

Requirements) Regulations, 2015, this is to inform you that Mr. Ratan Das – Chief
Financial Officer and Key Managerial Personnel of the Company has retired on 31st
March 2022 at the end of closure of business hours upon his attaining the age of
superannuation.

Further, the details/disclosures required under Regulation 30 of the SEBI Listing

Regulations, read with Schedule III thereto and the SEBI Circular No.
CIR/CFD/CMD/4/2015 dated September 9, 2015 (“SEBI Circular”), is enclosed herewith
as Annexure.

Please take the above on your records.

Thanking you,
Yours faithfully,
For Genesys International Corporation Limited

Vineet Chopra
Vice President - Legal & Company Secretary
Encl.: As above

Regd. Office: 73-A, SDF-III, SEEPZ, Andheri (E),

Mumbai-400 096, India Tel.: +91-22-2829 0303;
+91-22-4488 4488; Fax: +91-22-2829 0603
Website: www.igenesys.com;
email:investors@igenesys.com
CIN: L65990MH1983PLC029197
 Annexure

Disclosure under Regulation 30 of the SEBI Listing Regulations, read with Schedule III
thereto and SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015

SI.No Particulars Details

1. Reason for Change Retirement from Services of the Company
upon attaining age of superannuation.
2. Date of cessation With effect from close of business hours
on 31st March, 2022
3. Brief Profile Not applicable
4. Disclosure of relationships Not applicable
between directors (in case of
appointment of a director)

*****************************************************************************

Regd. Office: 73-A, SDF-III, SEEPZ, Andheri (E),

Mumbai-400 096, India Tel.: +91-22-2829 0303;
+91-22-4488 4488; Fax: +91-22-2829 0603
Website: www.igenesys.com;
email:investors@igenesys.com
CIN: L65990MH1983PLC029197
March 31, 2022
To,
National Stock Exchange of India Limited BSE Limited
Exchange Plaza, 5th Floor, Corporate Relationship Department,
Plot No. C/1, G Block, 2nd Floor, New Trading Wing,
Bandra – Kurla Complex, Rotunda Building, P.J. Towers,
Bandra (E), Mumbai -400 051 Dalal Street, Mumbai – 400 001

Symbol: SJS Scrip Code: 543387

ISIN: INE284S01014

Dear Sir/Madam,

Subject: Intimation of Schedule of Investors Meeting/ Analysts Call pursuant to Regulation 30 of the
SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure
Requirements) Regulations, 2015, we would like to inform you that we would be having group investor
meetings through calls/video conference during our participation in meeting organized by IDBI Capital, on
1st April, 2022.
Schedule of Institutional Investor Meetings
Date Particulars of Meeting/ Interaction Type Mode/ Venue
1st April, 2022 HDFC Life Insurance, Group Call Virtual
Mahindra ManuLife Mutual Fund,
New India Assurance,
Abakkus Asset Managers,
BOI Axa Mutual Fund

Please note that the Schedule may undergo change due to exigencies on the part of Investors / Company.
This is to further inform that the copy of the Investor Presentation has been uploaded on the Stock
Exchanges and is also available on the website of the Company at https://www.sjsindia.com/
Request you to kindly take the above on record.

Thanking you.
Yours faithfully,
For S.J.S. Enterprises Limited

_______________________
Thabraz Hushain W.
Company Secretary and Compliance Officer
Membership No.: A51119
March 31, 2022

The Manager The Manager

Corporate Relationship Department Listing Department
BSE Limited National Stock Exchange of India Limited
Floor 25, Phiroze Jeejeebhoy Towers Exchange Plaza, Bandra Kurla Complex
Dalal Street Bandra (East)
Mumbai – 400 001 Mumbai - 400 051

BSE Scrip Code- 533267 NSE Scrip Symbol: CANTABIL and Series: EQ
Fax No.: 022-2272 3121/1278/1557/3354 Fax No.: 022-26598237/38

Dear Sir,

Sub: Intimation Under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement)
Regulation, 2015

We submit herewith the intimation under regulation 30 of SEBI (Listing Obligation and
Disclosure Requirements), Regulation, 2015 that company has opened 3 New Showrooms/
Shops at different location in India during the month of March 2022. Now total number of
Showrooms/ Shops of the Company stands at 378.

Request you to please take on records.

Thanking You

Yours faithfully
 Date: 31.03.2022

To,
The Listing Compliance
BSE Ltd.
PhirozeJeejeebhoy Towers
Dalal Street
Mumbai- 400001

BSE Scrip Code: 541601

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements)
Regulations, 2015 –Resignation of Statutory Auditors of the Company.

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read SEBI Circular
No. CIR/CFD/CMD1/114/2019 dated October 18, 2019, we wish to inform that M/S. Anand Jain & Associates, Chartered
Accountants (Firm Registration No.: 105666W) have resigned as the Statutory Auditors of the company with effect from
March 29, 2022.

Details with respect to resignation/ change in Auditors of the Company as required under Regulation 30 Read with
Schedule Ill of the Listing Regulations, SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015 and
CIR/CFD/CMD1/114/2019 dated October 18, 2019 are annexed herewith.

Kindly take the same on record.

Thanking you,

Yours faithfully,

For, RAJNISH WELLNESS LIMITED

RAJNISH Digitally signed by

RAJNISH KUMAR SINGH
KUMAR Date: 2022.03.31
SINGH 15:48:34 +05'30'

RAJNISHKUMAR SINGH

MANAGING DIRECTOR

DIN: 07192704
Details with respect to change in Auditors of the Company as required under Regulation 30 Read with Schedule Ill of the
Listing Regulations and SEBI Circular CIR/CFD/CMD/4/2015 dated September 09, 2015

Resignation of Statutory Auditors

Particulars Details
Name of the Company Rajnish Wellness Ltd
Name of Auditor M/S. Anand Jain & Associates, Chartered Accountants
(Firm Registration No.: 105666W)
Reason for Change viz., appointment, Resignation due to disagreement w.r.t. Change in the
resignation, removal, death or Audit Fees as proposed by Statutory Auditors
otherwise
Effective Date of resignation March 29, 2022
Brief profile Not Applicable
Disclosure of relationships between Not Applicable
directors (in case of appointment of a
director)
 GUJARAT INDUSTRIES POWER COMPANY LTD.
Regd.Office: P.O.Ranoli- 391350, Dist. Vadodara, Gujarat -INDIA
CIN:L99999GJ1985PLC007868

SEC:REGU30:ID:2022 Date: 3Pt March, 2022

The General Manager The General Manager

Corporate RelationsDepartment Listing Department
BSELtd. National Stock Exchangeof India Ltd.
1st Floor, New Trading Ring "ExchangePlaza",C-I,Block 'G',
Sir PhirozeJeejeebhoy Towers, DalalStreet, Bandra-Kurla Complex, Bandra (East)
Mumbai: 400 001. Mumbai: 400051.
Scrip Code: 517300. Scrip Symbol: GIPCL.

Ref.: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)

Regulations, 2015.

Sub.: Changein Director - Cessation of Directorship of Shri S B Dangayach(DIN: 01572754).

Dear Sir/ Madam,

Pursuant to the provisions of Regulation 30(2) read with ParaA of Part A of Schedule III of the
SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to
inform that Shri S B Dangayach (DIN: 01572754), Independent Director of the Company, has
been appointed w.e.f. 3pt March, 2021 for a second term of a period of one (01) year, from
the date of his appointment and consequent upon completion of the said term of one (01)
year on 30th March, 2022, Shri S B Dangayach(DIN: 01572754), Independent Director, ceased
to be the Director of the Company with cessationdate of 30th March, 2022.

Kindly take the above on your records and acknowledge the receipt.

Thanking you,

ustries Power Company Ltd.

Company Secretary &

Compliance Officer

Regd. Office & Vadodara Plant: Surat lignite Power Plant:

P.O. Ranoli - 391350, Dist. vadodara, Gujarat -INDIA Village: Nani Naroli, Tal. Mangrol, Dist: Surat 394110 Gujarat, INDIA
Phone: EPABX(0265) 2232768 Fax: 2230029 Phone: EPABX(02629) 261063 to 261072 Fax: 261080
Email: asthakkar@gipcl.com Email: genslpp@gipcl.com
Website: www.gipci.com
 PARAS DEFENCE & SPACE TECHNOLOGIES LIMITED
Corporate & Registered Office:
0-112, TTC Indl. Area, Nerul, Navi Mumbai - 400706, India | Tel: +91-22-6919 9999 | Fax : +91-22-6919 9990
CIN # U29253MH2009PLC193352 | E-mail: business@parasdefence.com | Web : www.parasdefence.com

March 31, 2022

BSE Limited
National Stock Exchange of India Limi
Phiroze Jeejeebhoy Towers, ted
Exchange Plaza, Plot C/1, G Block,
Dalal Street,
Bandra — Kurla Complex,
Fort, Mumbai — 400 001
Bandra — (East), Mumbai — 400 051
Scrip Code: 543367
Trading Symbol: PARAS
Dear Sir’s,

Sub: Outcome of Independent Director's Meeti

ng of the Company held on March 31 2022
In accordance with the Provisions of clause VII of Schedule
IV of the Companies Act, 2013 and
Regulation 25 of the "Securities & Exchange
Board of India (Listing Obligations and Disclosure
Requirements) Regulations, 2015", it is submitted
that a separate meeting of the Independent
Directors of the Company was held today i.e. March
31, 2022, through video conferencing, wherein,
the following items in agenda were considered and discus
sed:
(i) Review of the performance of non - Independent Direct
ors of the company and the Board of
Directors as a whole.
(ii) Assess the quality, quantity and timeliness of flow of
information between the company
management and the Board that is necessary for the Board
to effectively and reasonably
perform their duties.

We request you to take the above on record and disseminate

the same on your website.

Thanking You.

echnologies Limited

Company Secretary and Compliance Officer

Heavy Engineering Divn. : M-6, Addl. MIDC, Ambernath (E), Thane - 421506, Maharashtra, India | Tel: +91-9820 965 96S | Fax : +91-251-2621 222
R & D Centre : No.1, 9th Cross, 9th Main, Malleshwaram, Bengaluru - 560 003, India | Tel: +91-9820 965 965 | Fax : +91-80-2346 4142
 March 31, 2022

To,
Corporate Communication Department Listing Department
BSE Limited National Stock Exchange of India Limited
Phiroze Jeejeeboy Towers, Exchange Plaza, Bandra Kurla Complex,
Dalal street, Mumbai - 400 001. Bandra (East), Mumbai - 400 051.
BSE Scrip Code : 532528 Symbol : DATAMATICS

Sub.: Disclosure under Regulation 30(6) of SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and
other applicable provisions, this is to inform you that the Company’s Management had a meeting
with the Institutional Investors/Analysts as per details given below:-

Date Interacted with Discussion Venue

March 31, 2022 GIC, Singapore – India Equity Industry/ Company specific Virtual
Investment developments already in public
domain

No unpublished price sensitive information was shared/discussed at the meeting.

Kindly take the above on your record.

Thanking you,

For Datamatics Global Services Limited

DIVYA Digitally signed

by DIVYA KUMAT

KUMAT 16:18:13 +05'30'

Date: 2022.03.31

__________________
Divya Kumat
EVP, Chief Legal Officer and Company Secretary
(FCS: 4611)

DATAMATICS GLOBAL SERVICES LTD.

Knowledge Centre, Plot 58, Street No. 17, MIDC, Andheri (East), Mumbai - 400 093. INDIA | Tel: +91 (22) 6102 0000/1/2
| Fax: +91 (22) 2834 3669 | CIN: L72200MH1987PLC045205 | business@datamatics.com | www.datamatics.com
2
>.l
MUMBAI | THURSDAY, 31 MARCH 2022 1
l.
MUMBAI | THURSDAY, 31 MARCH 2022 THE SMART INVESTOR 3 <

Big pharma firms to gain most Invest by 5th of a month

from price rise, say analysts to optimise return on PPF
Start of financial year is best time to put money into these taxsavers
Essential medicines set to get costlier from April 1 after pricing regulator’s nod
BINDISHA SARANG ution to the PPF account by a few
HARSHITA SINGH Cascading effect days, you lose out on interest
New Delhi, 30 March The price revision can also trigger A Public Provident Fund (PPF) income of ~888 for the month.
a price escalation of non-sched- investment offers a tax-free This difference may seem

T
he effects of inflation have uled formulations (83 per cent of return of 7.1 per cent. Among gov- small. However, PPF is a 15-year
spilled over to several domestic market sales) by 5-10 ernment-backed fixed-income instrument that can be
industries with many of per cent, analysts said. Ceiling schemes, only Employee’s extended further. The com-
them forced to raise prices to prices of non-scheduled drugs are Provident Fund (or EPF, which pounding effect over such a long
stave off rising cost pressures. not capped by the regulator, gives 8.1 per cent) and Sukanya period means you would lose a
With this, even essential medi- unlike for scheduled drugs, and Samriddhi Yojana (SSY, which considerable amount due to this
cines are set to become costlier these are permitted to be raised gives 7.6 per cent) offer higher PPF: A MUST-HAVE small mistake.
from April 1 as the National by not more than 10 per cent tax-free returns. One significant n PPF enjoys tax deduction Aggarwal says, “Even if you
Pharmaceutical Pricing Authority every year. point investors must remember under Section 80C of up to invest in PPF in tranches, do so
has allowed companies to hike “Companies with larger and while investing in PPF is that ~1.5 lakh by the 5th of the month to earn
prices of scheduled drugs by up wider focus on domestic formu- they must put in the money at maximum interest.”
SHOT IN THE ARM n It enjoys EEE (exempt-

71.0
to 10.8 per cent, the highest ever lations will relatively benefit the right time to maximise the
in the last 10 years. n India sales: Exposure to NLEM drugs (%) more and will likely see better re- return they earn from it. exempt-exempt) tax status Safe instrument, high return
Scheduled drugs (which make n India sales as % of total M9FY22 sales (%) n FY21-24e EPS CAGR (%) rating and investor interest,” said n There is a sovereign Even in long-term portfolios,
up 17 per cent of the domestic Surya Patra, vice president, How interest is calculated guarantee on it such as retirement, you need to
33.0

47.0

pharma market sales) fall under healthcare & specialty chemical An investor can deposit up to ~1.5 have a fixed-income component
47.0

n Creditors cannot attach

the national list of essential med- research at Phillip Capital. lakh in a PPF account each finan- of at least 20 per cent or more for
25.0

25.0
icines (NLEM), the prices of That said, the domestic cial year. The minimum one can PPF investment for stability. This part of the portfolio
18.10
17.60

repayment of debt to them

10-15

which are directly capped by the pharma market sales growth has invest is ~500 per month. should be constituted using
10.20 n One can avail of loan
8-10

9.90

government and are raised been highly volatile over the last Dilshad Billimoria, board instruments like EPF and PPF.
annually in sync with the whole- few months. For February, the member, Association of against your PPF deposit EPF contribution of only up
sale price inflation (WPI). sector registered a flat 1.1 per cent Registered Investment Advisors after the 3rd year to ~2.5 lakh is tax free.
The recent price hike will growth as volumes slipped. The (ARIA) says, “Interest on PPF is Contribution above this amount
n Premature withdrawals
cover over 800 of these drugs Sun Pharma Cipla Ipca Lab Alkem Lab growth for financial year 2022-23 earned on a monthly basis but is taxable at slab rate. The tax-
across various therapies. The (FY23) could further be weak on credited to the PPF account at
are permitted in case of free return from SSY is only avail-
development, analysts said, 1,030 1,175 1,300 3,950 a high base of Covid-19-hit FY22. the end of the year.” important milestones like able to people who have a girl
brings some respite for the indus- HSBC Global, however, Interest is calculated on the child’s education and child. For the self-employed, who
try facing multiple headwinds Target price (~) believes the NLEM price hike can lowest balance between the 5th marriage among others do not have access to EPF, PPF
such as steep raw material infla- Source: HSBC report help the sector deliver high single and the end of each month. Source: ARIA becomes even more crucial.
tion, price erosion in the US mar- to low double-digit growth in Adhil Shetty, chief executive PPF’s tenure can be extended.
ket and higher freight costs. Sun Pharma are the biggest ben- pressures as prices of key active FY23, assuming an additional officer (CEO), Bankbazaar says, account balance on March 31, Billimoria says, “Investors can
Companies with high expo- eficiaries as these companies pharmaceutical ingredients price rise of 5-8 per cent for non- “Deposit your contribution on or 2021 was ~15 lakh. You invest the extend PPF for as long as they
sure to NLEM drugs in their sales have 25-40 per cent exposure to (APIs) such as paracetamol have scheduled drugs too. Kotak before the 5th of the month so maximum permitted amount of like in blocks of five years. We
portfolio, analysts believe, will NLEM drugs, according to ana- risen 15-125 per cent, while excip- Institutional Equities adds that that it earns interest for that ~1.5 lakh as a fresh contribution recommend doing so. All exten-
benefit the most. lysts at Anand Rathi. ient prices have increased 20-250 NLEM price increase presents a month.” on April 3. Your PPF balance on sions have a lock-in period of five
Among the lot, Cipla, Alkem “With the new effective prices, per cent over the past 12-15 potential 150-200 basis points If you invest after the 5th, April 3 becomes ~16.5 lakh. The years only.”
Labs, JB Chemicals, Zydus Life companies should be able to pass months,” wrote Damayanti Kerai, upside to its 4-11 per cent year- that tranche of your investment minimum balance While PPF can help
Sciences, Dr Reddy's, GSK on some of the input price an analyst at HSBC Global in a on-year domestic growth esti- will not earn interest as it will between April 5 and you save tax and invest
Pharma, Lupin, Ipca Labs and increase to partially ease cost recent note. mates for FY23. be calculated on it only from the April 30 also stands at systematically for
next month. ~16.5 lakh. So, for the retirement and other
month of April, your long-term goals, you
Don’t lose out by investing late account will earn inter- cannot rely on it alone.
Sebi tightens rule for ‘passive breaches’ by mutual fund houses If you are planning to invest a
lump sum in PPF, do so before
est at the rate of 7.1 per
cent on ~16.5 lakh,
“The interest rate of
7.1 per cent beats infla-
The Securities and Exchange Board of India
(Sebi) has tightened rules around rectification
In a circular, Sebi has said all MF schemes,
other than index and exchange traded funds,
deadline, it will be barred from launching any
new scheme till the time the portfolio is rebal-
April 5.
Gaurav Aggarwal, senior
which equals ~9,762.
Now, suppose that
YOUR tion by barely about one
percentage point. This
and reporting of ‘passive breaches’ by mutual will get 30 days to rectify any passive breaches. anced. Further, it will not be allowed to levy exit director, Paisabazaar.com says, you make the same MONEY rate of return is not suf-
fund (MF) schemes. A passive breach is when a In case of a failure the fund management team load on the investors exiting such schemes. “The best time to invest in PPF contribution on April 7. ficient for building a
scheme’s asset allocation inadvertently deviates will have to give a justification in writing, includ- Under the new rules, which come into effect on is at the start of a financial year. The minimum balance between hefty corpus,” says Shetty.
from its scheme information document (SID). ing details of efforts taken to rebalance the port- July 1, 2022, Sebi has also increased the disclo- This way the investor can earn April 5 and April 30 in this case When your investment hori-
This could happen because of large-scale folio, to the investment committee (IC). The IC sure requirements for passive breaches, where interest on the deposit for the will be ~15 lakh. The interest zon is seven years or more, have
redemptions or sharp fall in the price of security then can extend the timeline to up to 60 days. If the fund house would have to report any devi- entire year.” earned on this amount will be a considerable allocation to
where the scheme has a large exposure. the fund house fails to meet even the extended ation to its trustee at each stage. BS REPORTER Suppose that your PPF ~8,875. Just by delaying contrib- equities.
Joshi Bakhru,
 CIN No.L17119DN1990PLC000091
FILATEX INDIA LIMITED
FIL/SE/2021-22/72
31st March, 2022
BSE Limited
National Stock Exchange of India Limited Listing Department
Listing Department 25th Floor, Pheroze Jeejeebhoy Towers
5th Floor, Exchange Plaza, C -l, Block-G, Dalai Street,
Bandra-Kurla Complex, Bandra (E) Mumbai - 400 001
Mumbai-400 051 Security Code: 526227
Security Symbol: FILATEX

Subject : Submission of Public Announcement and Board Resolution for the Buyback of Equity Shares of
Filatex India Limited (‘the Company’) through Tender Offer process in terms of the provisions of
Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018.

Dear Sir/Madam,

This is in furtherance to our outcome letter no. FIL/SE/2021-22/70 dated March 29, 2022, informing about the decision
of the Board of Directors o f the Company to buyback upto 42,50,000 (Forty-Two Lakh and Fifty Thousand Only)
fully paid-up Equity Shares of face value of Rs. 2/- each of the Company at a price o f Rs. 140/- (Rupees One Hundred
and Forty Only) per Equity Share payable in cash for an aggregate amount o f upto Rs. 59,50,00,000 (Rupees Fifty-
Nine Crore and Fifty Lakh Only), on a proportionate basis through the tender offer process in terms of the provisions of
Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018 (“Buyback Regulations”).

Please find enclosed herewith a copy of the Public Announcement dated March 29, 2022 for Buyback of the Company,
published on March 31, 2022 in the below mentioned newspapers:

1. All India editions of “Business Standard” (English)

2. All India editions of “Business Standard” (Hindi)
3. Vapi edition of “Divya Bhaskar” (Gujarati Regional Language)

Copy of the Public Announcement will also be made available on the website of the Company at wwvt. Iilatex.com.

Pursuant to Regulation 5(vii) o f the Buyback Regulations, please also find attached a copy o f Board Resolution passed in
the said meeting of Board of Directors.

This is for your information and records please.

Thanking you

Yours truly
For Filatex India Limited

^ r» vJU eSb--

Raman Kumar Jha

Company Secretary & Compliance Officer

CORPORATE OFFICE REGD. OFFICE & WORKS SURAT OFFICE MUMBAI OFFICE

S. No. 274 Demni Road Bhageria House 321, Maker Chamber ■ V

Bhageria House
4 3 C o m m u n ity Centre Dadra - 396193 Ring Road Nariman Point
U.T. of-Dadra & Nagar Haveli Surat ■395002 Mumbai -400021
New Friends Colony
India India India
New Delhi - 110025, India
P +91.11.26312503,26848633/44 P +91.260.2668343/8510 P +91.261.4030000 P +91.22.22026005/06
F +91.260.2668344 F +91.261.2310796 F +91.22.22026006
F +91.11.26849915
E fildadra@filatex.com E filsurat@filatex.com E filmumbai@filatex.com
E fildelhi@filatex.com
Website: www.filatex.com
2
>.l
MUMBAI | THURSDAY, 31 MARCH 2022 1
l.
MUMBAI | THURSDAY, 31 MARCH 2022 THE SMART INVESTOR 3 <

Big pharma firms to gain most Invest by 5th of a month

from price rise, say analysts to optimise return on PPF
Start of financial year is best time to put money into these taxsavers
Essential medicines set to get costlier from April 1 after pricing regulator’s nod
BINDISHA SARANG ution to the PPF account by a few
HARSHITA SINGH Cascading effect days, you lose out on interest
New Delhi, 30 March The price revision can also trigger A Public Provident Fund (PPF) income of ~888 for the month.
a price escalation of non-sched- investment offers a tax-free This difference may seem

T
he effects of inflation have uled formulations (83 per cent of return of 7.1 per cent. Among gov- small. However, PPF is a 15-year
spilled over to several domestic market sales) by 5-10 ernment-backed fixed-income instrument that can be
industries with many of per cent, analysts said. Ceiling schemes, only Employee’s extended further. The com-
them forced to raise prices to prices of non-scheduled drugs are Provident Fund (or EPF, which pounding effect over such a long
stave off rising cost pressures. not capped by the regulator, gives 8.1 per cent) and Sukanya period means you would lose a
With this, even essential medi- unlike for scheduled drugs, and Samriddhi Yojana (SSY, which considerable amount due to this
cines are set to become costlier these are permitted to be raised gives 7.6 per cent) offer higher PPF: A MUST-HAVE small mistake.
from April 1 as the National by not more than 10 per cent tax-free returns. One significant n PPF enjoys tax deduction Aggarwal says, “Even if you
Pharmaceutical Pricing Authority every year. point investors must remember under Section 80C of up to invest in PPF in tranches, do so
has allowed companies to hike “Companies with larger and while investing in PPF is that ~1.5 lakh by the 5th of the month to earn
prices of scheduled drugs by up wider focus on domestic formu- they must put in the money at maximum interest.”
SHOT IN THE ARM n It enjoys EEE (exempt-

71.0
to 10.8 per cent, the highest ever lations will relatively benefit the right time to maximise the
in the last 10 years. n India sales: Exposure to NLEM drugs (%) more and will likely see better re- return they earn from it. exempt-exempt) tax status Safe instrument, high return
Scheduled drugs (which make n India sales as % of total M9FY22 sales (%) n FY21-24e EPS CAGR (%) rating and investor interest,” said n There is a sovereign Even in long-term portfolios,
up 17 per cent of the domestic Surya Patra, vice president, How interest is calculated guarantee on it such as retirement, you need to
33.0

47.0

pharma market sales) fall under healthcare & specialty chemical An investor can deposit up to ~1.5 have a fixed-income component
47.0

n Creditors cannot attach

the national list of essential med- research at Phillip Capital. lakh in a PPF account each finan- of at least 20 per cent or more for
25.0

25.0
icines (NLEM), the prices of That said, the domestic cial year. The minimum one can PPF investment for stability. This part of the portfolio
18.10
17.60

repayment of debt to them

10-15

which are directly capped by the pharma market sales growth has invest is ~500 per month. should be constituted using
10.20 n One can avail of loan
8-10

9.90

government and are raised been highly volatile over the last Dilshad Billimoria, board instruments like EPF and PPF.
annually in sync with the whole- few months. For February, the member, Association of against your PPF deposit EPF contribution of only up
sale price inflation (WPI). sector registered a flat 1.1 per cent Registered Investment Advisors after the 3rd year to ~2.5 lakh is tax free.
The recent price hike will growth as volumes slipped. The (ARIA) says, “Interest on PPF is Contribution above this amount
n Premature withdrawals
cover over 800 of these drugs Sun Pharma Cipla Ipca Lab Alkem Lab growth for financial year 2022-23 earned on a monthly basis but is taxable at slab rate. The tax-
across various therapies. The (FY23) could further be weak on credited to the PPF account at
are permitted in case of free return from SSY is only avail-
development, analysts said, 1,030 1,175 1,300 3,950 a high base of Covid-19-hit FY22. the end of the year.” important milestones like able to people who have a girl
brings some respite for the indus- HSBC Global, however, Interest is calculated on the child’s education and child. For the self-employed, who
try facing multiple headwinds Target price (~) believes the NLEM price hike can lowest balance between the 5th marriage among others do not have access to EPF, PPF
such as steep raw material infla- Source: HSBC report help the sector deliver high single and the end of each month. Source: ARIA becomes even more crucial.
tion, price erosion in the US mar- to low double-digit growth in Adhil Shetty, chief executive PPF’s tenure can be extended.
ket and higher freight costs. Sun Pharma are the biggest ben- pressures as prices of key active FY23, assuming an additional officer (CEO), Bankbazaar says, account balance on March 31, Billimoria says, “Investors can
Companies with high expo- eficiaries as these companies pharmaceutical ingredients price rise of 5-8 per cent for non- “Deposit your contribution on or 2021 was ~15 lakh. You invest the extend PPF for as long as they
sure to NLEM drugs in their sales have 25-40 per cent exposure to (APIs) such as paracetamol have scheduled drugs too. Kotak before the 5th of the month so maximum permitted amount of like in blocks of five years. We
portfolio, analysts believe, will NLEM drugs, according to ana- risen 15-125 per cent, while excip- Institutional Equities adds that that it earns interest for that ~1.5 lakh as a fresh contribution recommend doing so. All exten-
benefit the most. lysts at Anand Rathi. ient prices have increased 20-250 NLEM price increase presents a month.” on April 3. Your PPF balance on sions have a lock-in period of five
Among the lot, Cipla, Alkem “With the new effective prices, per cent over the past 12-15 potential 150-200 basis points If you invest after the 5th, April 3 becomes ~16.5 lakh. The years only.”
Labs, JB Chemicals, Zydus Life companies should be able to pass months,” wrote Damayanti Kerai, upside to its 4-11 per cent year- that tranche of your investment minimum balance While PPF can help
Sciences, Dr Reddy's, GSK on some of the input price an analyst at HSBC Global in a on-year domestic growth esti- will not earn interest as it will between April 5 and you save tax and invest
Pharma, Lupin, Ipca Labs and increase to partially ease cost recent note. mates for FY23. be calculated on it only from the April 30 also stands at systematically for
next month. ~16.5 lakh. So, for the retirement and other
month of April, your long-term goals, you
Don’t lose out by investing late account will earn inter- cannot rely on it alone.
Sebi tightens rule for ‘passive breaches’ by mutual fund houses If you are planning to invest a
lump sum in PPF, do so before
est at the rate of 7.1 per
cent on ~16.5 lakh,
“The interest rate of
7.1 per cent beats infla-
The Securities and Exchange Board of India
(Sebi) has tightened rules around rectification
In a circular, Sebi has said all MF schemes,
other than index and exchange traded funds,
deadline, it will be barred from launching any
new scheme till the time the portfolio is rebal-
April 5.
Gaurav Aggarwal, senior
which equals ~9,762.
Now, suppose that
YOUR tion by barely about one
percentage point. This
and reporting of ‘passive breaches’ by mutual will get 30 days to rectify any passive breaches. anced. Further, it will not be allowed to levy exit director, Paisabazaar.com says, you make the same MONEY rate of return is not suf-
fund (MF) schemes. A passive breach is when a In case of a failure the fund management team load on the investors exiting such schemes. “The best time to invest in PPF contribution on April 7. ficient for building a
scheme’s asset allocation inadvertently deviates will have to give a justification in writing, includ- Under the new rules, which come into effect on is at the start of a financial year. The minimum balance between hefty corpus,” says Shetty.
from its scheme information document (SID). ing details of efforts taken to rebalance the port- July 1, 2022, Sebi has also increased the disclo- This way the investor can earn April 5 and April 30 in this case When your investment hori-
This could happen because of large-scale folio, to the investment committee (IC). The IC sure requirements for passive breaches, where interest on the deposit for the will be ~15 lakh. The interest zon is seven years or more, have
redemptions or sharp fall in the price of security then can extend the timeline to up to 60 days. If the fund house would have to report any devi- entire year.” earned on this amount will be a considerable allocation to
where the scheme has a large exposure. the fund house fails to meet even the extended ation to its trustee at each stage. BS REPORTER Suppose that your PPF ~8,875. Just by delaying contrib- equities.
Joshi Bakhru,
 KESORAM
www.kesocorp.com

KIL/SE/Reg.30/2021-22 Date: 31° March, 2022

BSE Ltd. oe National Stock Exchange of India| The Calcutta Stock

First Floor, New Trading Ring, | Ltd. Exchange Ltd.
Rotunda Building, Phiroze | “Exchange Plaza’, Plot no, C/1, G. | 7, Lyons Range,
Jeejeebhoy Towers, Dalal Street, | Block Bandra -Kurla Complex, Kolkata — 700001
Fort, Mumbai — 400001 Bandra (E), Mumbai — 400051
(Equity Scrip Code-502937) (NSE Symbol - KESORAMIND) (Scrip code-10000020)
(NCD Scrip Code
— 973060)

Dear Sir/Madam,

Sub: Part redemption of unlisted Optionally Convertible Debentures (“OCD”) to the tune of INR
15,45,26,400/-.

We wish to inform you that on March 31, 2022, the Company has made part redemption of Unlisted
Secured Redeemable Optionally Convertible Debentures (“OCD”) which were issued by the Company
on March 16, 2021. The details of which are provided hereunder:

Particulars ISIN Face Value | Date of | Outstanding

Amnt paid | payment / | OCD face
BC (INR) redemption __| value (INR)
Unlisted Secured | INEO87A07669 | 15,45,26,400 31/03/2022 150,57,12,600
Redeemable Optionally
Convertible Debentures
(“OCD”) 4599 nos of face
| valuc of INR 10,00,000 each
totalling to INR
459,90,00,000

This is for your kind information and records.

Yours faithfully,
For Kesoram Industries Limited

Raghuram Nath
Company Secretary

P +91 33 2243 5453, 2242 9454 Kesoram Industries Limited

+ 91 33 2248 0764, 2213 0441 Registered & Corporate Office :
F + 91 33 2210 9455 9/1, R.N, Mukherjee Road, Kolkata - 700 001
E ; corporate@kesoram.net CIN - L17119WB1919PLC003429
31st March, 2022

BSE Limited National Stock Exchange of India Limited

25th floor, Phiroze Towers, Exchange Plaza, 5th Floor, Plot No. C/1,
Dalal Street, G Block, Bandra - Kurla Complex,
Fort, Mumbai- 400001 Bandra (E), Mumbai - 400 051
Scrip code: 511742 Symbol: UGROCAP

Subject: Disclosure under Regulation 30 of Securities and Exchange Board of India (“SEBI”) (Listing
Obligations and Disclosure Requirements) Regulations, 2015- Appointment of Independent Director

Dear Sir/ Madam,

We wish to inform you that based on the recommendation of the Nomination and Remuneration Committee,
the Board of Directors of the Company has considered and approved the appointment of Mrs. Smita
Aggarwal (DIN 01478327) as an Additional Independent (Woman) Director of the Company w.e.f. today,
31st March, 2022.

The details required under Regulation 30 the SEBI Listing Regulations, read with SEBI Circular No.
CIR/CFD/CMD/4/2015 dated 9th September, 2015 for change in Directors are given in Annexure A.

This intimation is also being uploaded on the Company's website (www.ugrocapital.com).

Kindly take the above on record.

Yours faithfully,

For UGRO Capital Limited

Aniket Karandikar
Company Secretary

Encl: a/a

UGRO CAPITAL LIMITED

Registered Office Address: Equinox Business Park, Tower 3, 4th Floor, LBS Road, Kurla (West), Mumbai - 400070
CIN: L67120MH1993PLC070739
Telephone: +91 22 48918686 I E-mail: yougrow@ugrocapital.com I Website: www.ugrocapital.com
 Annexure A
Details with respect to change of Directors of the Company as required under Regulation 30 read
with Schedule III of the SEBI (LODR) Regulations, 2015 and SEBI Circular CIR/CFD/CMD/4/2015
dated 09th September, 2015:

Mrs. Smita Aggarwal

1 Reason for Change viz., appointment, Appointed as Additional (Independent) Director
resignation, removal, death or otherwise
2 Date of cessation & Not applicable
Term of appointment
3 Brief profile Mrs. Smita Aggarwal is listed in “Top 35 Global
Women in Fintech Powerlist”, ‘Top Women in
Finance’, “Top 30 Fintech Influencers” and “Women
Who Venture”, Mrs. Smita Aggarwal is a fintech
investor and a thought leader with deep expertise in
venture capital, financial inclusion, digital banking,
micro-insurance and financial regulation. She is
Global Investments Advisor for Flourish Ventures, a
global fintech focussed fund, and leads investments
in innovative fintech start-ups that help advance
financial health and inclusion in Asia. She is on the
Fintech Advisory Board of New York University and
Global Fintech Fest. She is a member of the Board
of Directors of IIFL Asset Management Company.
She is a guest faculty for “Fintech in Emerging
Markets” at the Stern School of Business, New York
University.

She has three decades of experience in finance as a

banker, lender, regulator and an investor that have
enriched her with unparalleled domain expertise,
unique perspective and empathy for fintech
founders. She has held leadership positions with
noteworthy names such as Omidyar Network,
Fullerton India Credit, Reserve Bank of India and
ICICI Bank with a successful track record of
building businesses from scratch, introducing new
products, and driving growth through innovation.
She is a rank-holder chartered accountant and has
attended executive programs at Harvard Business
School and MIT Sloan School of Management.
4 Disclosure of relationships between Mrs. Smita Aggarwal is not related to any Director
directors (in case of appointment of a of the Company.
director).

*****

UGRO CAPITAL LIMITED

Registered Office Address: Equinox Business Park, Tower 3, 4th Floor, LBS Road, Kurla (West), Mumbai - 400070
CIN: L67120MH1993PLC070739
Telephone: +91 22 48918686 I E-mail: yougrow@ugrocapital.com I Website: www.ugrocapital.com
 SpiceJet Limited
319 Udyog Vihar, Phase-IV,
Gurugram 122016, Haryana, India.
Tel: + 91 124 3913939
Fax: + 91 124 3913844

March 31, 2022

Department of Corporate Services,

BSE Limited,
Phiroz Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001

Reference: Scrip Code: 500285 and Scrip ID: SPICEJET

Subject: Disclosure under Regulation 30 of the SEBI (Listing

Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir,

This refers to Special Leave Petition(s) filed by the Company before the Hon’ble
Supreme Court of India against the winding up order passed by the Hon’ble High
Court of Judicature at Madras in Company Petition No. 363 of 2015 titled ‘Credit
Suisse AG v. SpiceJet Limited’.

In this regard, we wish to inform you that Credit Suisse AG and the Company have
now reached an in-principle commercial settlement of the dispute and the process of
documentation is underway.

The settlement with Credit Suisse AG follows the Company’s successful settlements
with the Boeing Company, De Havilland Aircraft of Canada Limited and Aircraft
Lessors such as CDB Aviation and Avolon.

This is for your information and further dissemination.

Thanking you,

Yours truly,
For SpiceJet Limited

Chandan Sand
Sr. VP (Legal) & Company Secretary

Registered Office: Indira Gandhi International Airport, Terminal 1D, New Delhi 110037, India. Website: www.spicejet.com
CIN: L51909DL1984PLC288239
 \Fqsåqlffi¿s
srøn il
( qira scm-q) e-assuring
MSTC LIMITEI)
(Â Govt. of lndia F)ntcrprisc)
¡il1ilA
(llN : 1,27320\\rlì196,1(J()102621 I

MSTC/CS/SE/31 7 31't March, 2022

1. The Dy. Manager (Listing) 2. The Manager, Listing Department

BSE Limited Nationat Stock Exchange of lndia Limited
Phiroze Jeejeebhoy Towers, Exchange Ptaza, Bandra Kurta Comptex
Dalal Street, Mumbai 400 001. Bandra (E), Mumbai 400 051
(Scrip Code: 5425971 (Scrip Code: MSTCLTD)

Dear Sir/Madam,

Sub: Disclosure under Requlation 30 of SEB| (Listinq Obliqation and Disclosure Requirements)
Requlation. 2015

Ref: Letter no. MSTC/C5/5E/285 dated 12.11.2021 and letter no. MSTC/CS/SE/297 dated
22.12.2021 from MSTC Limited to the Stock Exchanees

Pursuant to Regulation 30 of SEBI (Listing Obtigations and Disctosure Requirements) Regutations,

2015, we woutd like to inform you that, Department of lnvestment and Pubtic Asset Management
(DIPAM), Ministry of Finance, Government of lndia, has pubtished advertisement in the prominent
newspapers on 31.03.2022 inviting Globat Expression of lnterest (EOls) from the lnterest Bidders
(lBs) for proposed strategic Disinvestment of entire equity sharehotding in Ferro Scrap Nigam
Limited (FSNL) - a 100% subsidiary of MSTC Ltd atong with transfer of management controt.

A copy of said newspaper advertisement is attached herewith for your information and records.

The detaited Pretiminary lnformation Memorandum (PlM) / Gtobat lnvitation for Expression of
lnterest (EOl) is uptoaded/pubtished on the website of the company at
https: / /www. mstcindia.co.in/MSTC_Static_Pages/ HighLight/ PIM_EOl_FSNL_Finat_30032022.pdf
and atso on the websites of DIPAM, Ministry of Steel, FSNL and BDO lndia LLP (Transaction
Advisers) so as to give wider pubticity and assess to the lBs.

Kindty take the above intimation on your records.

Thanking you,

Yours faithfutty,
For MSTC Limited

(Ajay Kunìar Rai)

Company Secretary and Compliance Officer

wwrv.nrstcindi¿t.co.i n / wrvw. mstcccont nle rcc.co nr

.ifi¡n ørql-d{r ' .d-¿ €. ûqw ltt/2, qFl .{. 175, \pcn qft¿n t rfr, gerw ol-at¡rol-zo0 l 5 6 , e.a
Il.cgtl. Oflicc : Plot No, (llìlll/2, Strcet No. 175, Action Area l(1, Nur''lolvn, Kolkata - 700 156 W.¡i.
 March 31, 2022
matrimony.com
· onal Stock Exchange of India Ltd Corporate Relationship Department
Exchan laza, 5th Floor BSE Ltd.,
Plot No: C/1, ck Phiroze Jeejheebhoy Towers
Sandra Kurla Complex, �-·� Dalal Street, Mumbai - 400 001
Mumbai - 400 051

Dear Sirs,
Sub: Intimation of outcome of the Board Meeting under Regulation 30 (4) SEBI (Listing
Obligations and Disclosure Requirements) Regulations, 2015
Ref: Scrip Code - BSE: 540704: NSE: MATRIMONY
Pursuant to Regulation 30 (4) of SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015 (LODR), the Board of Directors of the Company at their meeting held on
March 31, 2022, have approved the sale of land ("Land") which was purchased out of
proceeds of the fresh issue of the initial public offering of the Equity Shares of the Company
("IPO") as stated in the Prospectus dated September 14, 2017 subject to shareholders
approval.
The land was purchased for the construction of office premises in Chennai. The Company
has been contemplating to construct an office at the proposed site since listing but could not
construct an office. Post covid 19 pandemic, the Company has decided not to pursue the
object of constructing a corporate office. The Company also believes that the current model
of using the leased premises is a more commercially viable option. The Land has been unused
since its purchase and is currently not yielding any income. Accordingly, the Company
believes that rather than keeping a depreciating, non-income generating asset on its books, it
would be financially prudent to sell the Land and utilise the proceeds of the sale towards
advertising and business promotion to scale up its business, acquire new users and expand
its existing and new products and services in current and newer markets. In summary, while
the Company utilised INR 42.58 crores from the IPO proceeds towards purchase of the Land
in pursuance of Object No. 2 as stated in the Prospectus, it does not intend to construct office
premises or;i the Land. Instead, the Company proposes to sell the · Land and utilise the
proceeds from such sale towards strategic advertising and business promotion activities.
While there is ambiguity as to whether such sale constitutes a change in the objects of the
IPO, in light of the high standards of corporate governance followed by the Company, it seeks
shareholders' approval for sale of the Land and to use those proceeds for the purposes
mentioned above (in accordance with Section 27 of the Companies Act, 2013, the rules framed
thereunder and other applicable law).
Submitted for your information and records.
Thanking you,
Yours faithfully
For Matrimony.com Limited

S�and
Company Secretary & Compliance Officer
ACS: 18951
No.94, TVH Beliciaa Towers, Tower II, 5th Floor, MRC Nagar, Raja Annamalaipuram
Chennai - 600028
matrimony.com ltd.
. . ( GIN: L63090TN2001PLC047432)
Corporate & Registered Offi e No 94

:
c . .
. T e c aa
:
e
i
VH B ll , Ti���� �: � 5�h �1
9 1
fto�R� a l u
3��i�o:ij Annarna ai P rarn,
Chenn ai, Tamil Nadu - 600 028.
 MAX. "VENTURES&
INDUSTRIES
�

March 31, 2022

Listing Department Listing Department

BSE Limited National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers Exchange Plaza, Bandra Kurfa Complex,
Dalal Street Bandra (East)
Mumbai - 400 001 Mumbai - 400051

Scrip Code: 639940 Name of Scrip: MAXVIL

Sub.: Intimation of Schedule of Analyst / lnatltutlonal Investor meetings under the SEBI
(Listing Obllgatlona and Dl■cloaure Requirements). Ragulatlon■ 2015

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements},

Regulations 2015, we wish to inform you that the officials of the Company will be meeting
Investors and Analysts (Participants}, the details of which are below.

Data Eva Place

This is to further inform that the Company will be referring to the Investor Presentation available
on the website of the Company www.maxvil.com and submitted to the Stock Exchanges on
January 23, 2022. This is for your information and also for the information of your members and
the public at large.

Kindly note that changes may happen due to exigencies on the part of Participants/ Company.

You are requested to take note of the above.

□�,�
Thanking you,

Yours faithfully,

For Max Ventures an imltad

. • L. � ""
§ "
cECD
�$.
l • •
� CD
7
.�J:
* "';
Nitin Kumar Kansai � ·
Chief Financial Officer 1l'

Max Ventures and Industries Limited

I
Corporate Office: Max Towers, L-12, C-001/A/1, Sector-16B, Noida- 201301, Uttar Pradesh, India P; +91 120-4743222
Regd. Office; 419, Bhai Mohan Singh Nagar, Village Railmajra, Tehsil Balachaur, Dist. S.B.S. Nagar (Nawanshahr), Punjab 144 533, India
E-Mail: secretarial@maxvil.com
CIN: L85100PB2015PLC039204
 PUNJAB CHEMICALS
AND CROP PROTECTION LTD.
CIN NO. L24231PB1975PLC047063
Regd. Office & Works
Milestone-18, Ambala-Kalka Road, Village& P.O, Bhankharpur, Derabassi, Distt SAS Nagar, Mohali (Punjab)-140201, INDIA
Tele: 01762-280086, 522250, Fax: 01762-280070, E-mail: info@punjabchemicals.com, Website: www.punjabchemicals.com

Date: 31st March, 2022

BY E FILING

The Manager The Manager

Department of Corporate Services Listing Department
BSE Limited National Stock Exchange of India Limited
MUMBAI-400 001 MUMBAI-400 051
Re: BSE Scrip Code: 506618 NSE Scrip Symbol: PUNJABCHEM

Sub: — Intimation of Interaction with Institutional Investors

Dear Sir,

In compliance with Regulation 30(2) of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015, we hereby inform that Mr Shalil Shroff - MD / Mr
Vinod Kumar Gupta- CEO / Dr Sriram Swaminathan- CFO, will be interacting with
the Institutional Investors / others as per detail given below:

Date/Time of Investor Call Investor/ | Type of Venue

Participant | Interaction

Thursday 31st March, 2022 at | Meeting with One to one Virtual conference
12 noon NW 18 Team by Dickenson
World.

The above schedule is subject to change due to exigencies, if any

We request you to take the above information on record.

Thanking you

Yours Faithfully
For PUNJAB CHEMICALS AND CROP PROTECTION LTD.

Van UP 7/1
RINIVAS
COMPANY SECRETARY & COMPLIANCE OFFICER
(ACS 37078)

Corporate Office; Oberoi Chambers Lf, 5th Floor, Plot No. 645/646, New link Road, Andheri (W), Mumbai-400053, INDIA. Tele: 91 -22-26747900, Fax: 91-22-26736178, Email: enquiry@punjabchemicals.com